Search hospitals > Pennsylvania > York
UPMC Memorial
Claim this profileYork, Pennsylvania 17408
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Squamous Cell Carcinoma
47 reported clinical trials
19 medical researchers
Summary
UPMC Memorial is a medical facility located in York, Pennsylvania. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Squamous Cell Carcinoma and other specialties. UPMC Memorial is involved with conducting 47 clinical trials across 85 conditions. There are 19 research doctors associated with this hospital, such as Liza C. Villaruz, Adam Brufsky, MD, Dan P. Zandberg, and Anuradha Krishnamurthy.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 positive
ER positive
Stage II
Top PIs
Liza C. VillaruzUniversity of Pittsburgh Cancer Institute (UPCI)5 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
37 reported clinical trials
53 drugs studied
Adam Brufsky, MDUniversity of Pittsburgh Cancer Institute (UPCI)1 year of reported clinical research
Expert in Breast Cancer
Studies Cancer
31 reported clinical trials
70 drugs studied
Dan P. ZandbergUniversity of Pittsburgh Cancer Institute (UPCI)1 year of reported clinical research
Expert in Cancer
Expert in Squamous Cell Carcinoma
18 reported clinical trials
33 drugs studied
Anuradha KrishnamurthyUniversity of Pittsburgh Cancer Institute (UPCI)4 years of reported clinical research
Studies Colorectal Cancer
Studies Cancer
18 reported clinical trials
32 drugs studied
Clinical Trials running at UPMC Memorial
Breast Cancer
Prostate Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Squamous Cell Carcinoma
Small Cell Lung Cancer
Renal Cell Carcinoma
Laryngeal Cancer
Prostate Adenocarcinoma
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Omitting Radiation Therapy
for Breast Cancer
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Recruiting2 awards Phase 319 criteria
Whole Brain Radiotherapy + Stereotactic Radiosurgery
for Brain Metastasis
This phase III trial compares the effect of adding whole brain radiotherapy with hippocampal avoidance and memantine to stereotactic radiosurgery versus stereotactic radiosurgery alone in treating patients with cancer that has spread to the brain and come back in other areas of the brain after earlier stereotactic radiosurgery. Hippocampus avoidance during whole-brain radiation therapy decreases the amount of radiation that is delivered to the hippocampus, which is a brain structure that is important for memory. The medicine memantine is also often given with whole brain radiation therapy because it may decrease the risk of side effects of radiation on thinking and memory. Stereotactic radiosurgery delivers a high dose of radiation only to the small areas of cancer in the brain and avoids the surrounding normal brain tissue. Adding whole brain radiotherapy with hippocampal avoidance and memantine to stereotactic radiosurgery may be effective in shrinking or stabilizing cancer that has spread to the brain and returned in other areas of the brain after receiving stereotactic radiosurgery.
Recruiting2 awards Phase 312 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at UPMC Memorial?
UPMC Memorial is a medical facility located in York, Pennsylvania. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Squamous Cell Carcinoma and other specialties. UPMC Memorial is involved with conducting 47 clinical trials across 85 conditions. There are 19 research doctors associated with this hospital, such as Liza C. Villaruz, Adam Brufsky, MD, Dan P. Zandberg, and Anuradha Krishnamurthy.